Search

Your search keyword '"Burnett, Alan K."' showing total 1,081 results

Search Constraints

Start Over You searched for: Author "Burnett, Alan K." Remove constraint Author: "Burnett, Alan K."
1,081 results on '"Burnett, Alan K."'

Search Results

1. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

2. Unified classification and risk-stratification in Acute Myeloid Leukemia

5. Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

6. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

8. A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI‐1 trial.

11. A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial

14. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia

16. A randomised evaluation of low‐dose Ara‐C plus pegylated recombinant arginase BCT‐100 versus low dose Ara‐C in older unfit patients with acute myeloid leukaemia: Results from the LI‐1 trial

17. Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG

18. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

20. Cardiac Complications

26. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)

29. Assessment of Minimal Residual Disease in Standard-Risk AML

34. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA

35. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

37. A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

38. A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

39. Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG

40. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial

41. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

45. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

48. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

49. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

Catalog

Books, media, physical & digital resources